

Michael G Dwyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9423883/publications.pdf>

Version: 2024-02-01

192
papers

6,632
citations

70961

41
h-index

88477

70
g-index

192
all docs

192
docs citations

192
times ranked

6511
citing authors

#	ARTICLE	IF	CITATIONS
1	Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2017, 69, 367-377.	1.2	405
2	Effect of a Cerebral Protection Device on Brain Lesions Following Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 592.	3.8	284
3	Neocortical Atrophy, Third Ventricular Width, and Cognitive Dysfunction in Multiple Sclerosis. <i>Archives of Neurology</i> , 2006, 63, 1301.	4.9	282
4	Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. <i>Journal of Neurology</i> , 2012, 259, 139-146.	1.8	274
5	Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis. <i>NeuroImage</i> , 2012, 59, 331-339.	2.1	176
6	Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis. <i>Radiology</i> , 2013, 268, 831-841.	3.6	145
7	Extent of cerebellum, subcortical and cortical atrophy in patients with MS. <i>Journal of the Neurological Sciences</i> , 2009, 282, 47-54.	0.3	133
8	Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 777-793.	1.4	126
9	Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: A pilot study. <i>Journal of the Neurological Sciences</i> , 2009, 282, 96-105.	0.3	110
10	Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2017, 69, 679-691.	1.2	110
11	Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. <i>NeuroImage</i> , 2007, 36, 1294-1300.	2.1	109
12	Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-310051.	0.9	95
13	Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 722-730.	1.4	91
14	Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1327-1336.	1.4	88
15	Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1478-1484.	1.4	85
16	Gray matter atrophy and disability progression in patients with early relapsing—remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2009, 282, 112-119.	0.3	84
17	Use of MR Venography for Characterization of the Extracranial Venous System in Patients with Multiple Sclerosis and Healthy Control Subjects. <i>Radiology</i> , 2011, 258, 562-570.	3.6	81
18	Validity of the Wisconsin Card Sorting and Delis—Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2007, 29, 215-223.	0.8	77

#	ARTICLE	IF	CITATIONS
19	Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a cross-sectional preliminary report. <i>BMC Medicine</i> , 2011, 9, 22.	2.3	77
20	Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis. <i>Radiology</i> , 2018, 289, 487-496.	3.6	75
21	A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1709-1718.	1.4	69
22	Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study. <i>PLoS ONE</i> , 2013, 8, e53996.	1.1	68
23	Jugular Venous Reflux and White Matter Abnormalities in Alzheimer's Disease: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 601-609.	1.2	67
24	The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. <i>Journal of Neurology</i> , 2008, 255, 61-74.	1.8	66
25	Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1757-1770.	1.7	66
26	White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. <i>NeuroImage</i> , 2009, 47, 2083-2089.	2.1	65
27	Cerebral Microbleeds in Multiple Sclerosis Evaluated on Susceptibility-weighted Images and Quantitative Susceptibility Maps: A Case-Control Study. <i>Radiology</i> , 2016, 281, 884-895.	3.6	63
28	Gray matter correlations of cognition in incident Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 629-633.	2.2	61
29	Iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging filtered phase: A case control study. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 36, 73-83.	1.9	60
30	Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality. <i>NeuroImage</i> , 2018, 167, 438-452.	2.1	60
31	Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. <i>NeuroImage: Clinical</i> , 2018, 17, 444-451.	1.4	58
32	Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 220-231.	1.4	55
33	Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological status in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 36-42.	1.4	53
34	Randomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 515-527.	1.1	53
35	Brain atrophy and white matter hyperintensities in early Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2233-2241.	2.2	50
36	Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency. <i>BMC Neurology</i> , 2011, 11, 128.	0.8	50

#	ARTICLE	IF	CITATIONS
37	Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2018, 28, 490-495.	1.0	50
38	Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field model. <i>NeuroImage</i> , 2014, 90, 207-217.	2.1	48
39	Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2017, 15, 769-779.	1.4	48
40	Cine cerebrospinal fluid imaging in multiple sclerosis. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 36, 825-834.	1.9	46
41	Evidence of progressive tissue loss in the core of chronic MS lesions: A longitudinal DTI study. <i>NeuroImage: Clinical</i> , 2018, 17, 1028-1035.	1.4	46
42	Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. <i>NeuroImage</i> , 2007, 36, 746-754.	2.1	45
43	Cortical atrophy and personality in multiple sclerosis.. <i>Neuropsychology</i> , 2008, 22, 432-441.	1.0	44
44	Odor identification deficit in mild cognitive impairment and Alzheimer's disease is associated with hippocampal and deep gray matter atrophy. <i>Psychiatry Research - Neuroimaging</i> , 2016, 255, 87-93.	0.9	42
45	Short-term brain atrophy changes in relapsing—remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2004, 223, 185-193.	0.3	41
46	A randomized evaluation of the TriGuard— HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial. <i>European Heart Journal</i> , 2021, 42, 2670-2679.	1.0	39
47	White Matter Hyperintensities and Mild Cognitive Impairment in Parkinson's Disease. <i>Journal of Neuroimaging</i> , 2015, 25, 754-760.	1.0	38
48	Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2018, 39, 642-647.	1.2	38
49	Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials. <i>European Heart Journal</i> , 2018, 39, 1687-1697.	1.0	38
50	Recovery of cognitive function after relapse in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 71-78.	1.4	38
51	Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis. <i>Human Brain Mapping</i> , 2019, 40, 5231-5241.	1.9	37
52	Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective. <i>Vaccines</i> , 2020, 8, 50.	2.1	37
53	Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1075-1081.	0.9	36
54	An improved FSL-FIRST pipeline for subcortical gray matter segmentation to study abnormal brain anatomy using quantitative susceptibility mapping (QSM). <i>Magnetic Resonance Imaging</i> , 2017, 39, 110-122.	1.0	36

#	ARTICLE	IF	CITATIONS
55	Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. <i>Radiology</i> , 2019, 293, 424-433.	3.6	36
56	Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study. <i>Journal of Neurology</i> , 2019, 266, 866-875.	1.8	36
57	Diffusion Tensor Imaging Alterations in Patients With Postconcussion Syndrome Undergoing Exercise Treatment. <i>Journal of Head Trauma Rehabilitation</i> , 2015, 30, E32-E42.	1.0	34
58	Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1243-1254.	1.4	33
59	Aging and Brain Atrophy in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2019, 29, 527-535.	1.0	33
60	Changes of deep gray matter magnetic susceptibility over 2 years in multiple sclerosis and healthy control brain. <i>NeuroImage: Clinical</i> , 2018, 18, 1007-1016.	1.4	32
61	Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals. <i>NeuroImage: Clinical</i> , 2018, 17, 530-540.	1.4	32
62	Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 541-553.	1.4	32
63	Jugular venous reflux and brain parenchyma volumes in elderly patients with mild cognitive impairment and Alzheimer's disease. <i>BMC Neurology</i> , 2013, 13, 157.	0.8	31
64	Aqueductal cerebrospinal fluid pulsatility in healthy individuals is affected by impaired cerebral venous outflow. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 1215-1222.	1.9	31
65	Deep grey matter injury in multiple sclerosis: a NAIMS consensus statement. <i>Brain</i> , 2021, 144, 1974-1984.	3.7	31
66	Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS. <i>Neurology</i> , 2019, 93, e611-e623.	1.5	30
67	A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2010, 3, 15-28.	1.5	29
68	Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 567-576.	1.4	28
69	Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e427.	3.1	28
70	Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 322-332.	1.4	28
71	Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2016, 37, 1010-1016.	1.2	27
72	Decreasing brain iron in multiple sclerosis: The difference between concentration and content in iron MRI. <i>Human Brain Mapping</i> , 2021, 42, 1463-1474.	1.9	27

#	ARTICLE	IF	CITATIONS
73	Reproducibility and Accuracy of Quantitative Magnetic Resonance Imaging Techniques of Whole-Brain Atrophy Measurement in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2005, 15, 27-36.	1.0	26
74	Signal abnormalities on 1.5 and 3 Tesla brain MRI in multiple sclerosis patients and healthy controls. A morphological and spatial quantitative comparison study. <i>NeuroImage</i> , 2009, 47, 1352-1362.	2.1	26
75	Establishing pathological cut-offs for lateral ventricular volume expansion rates. <i>NeuroImage: Clinical</i> , 2018, 18, 494-501.	1.4	26
76	Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage. <i>Journal of the Neurological Sciences</i> , 2018, 393, 128-134.	0.3	26
77	Detection of Cortical Lesions is Dependent on Choice of Slice Thickness in Patients with Multiple Sclerosis. <i>International Review of Neurobiology</i> , 2007, 79, 475-489.	0.9	25
78	Multimodal Imaging of Retired Professional Contact Sport Athletes Does Not Provide Evidence of Structural and Functional Brain Damage. <i>Journal of Head Trauma Rehabilitation</i> , 2018, 33, E24-E32.	1.0	25
79	Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine. <i>American Journal of Neuroradiology</i> , 2018, 39, 2237-2242.	1.2	25
80	Assessment of mesoscopic properties of deep gray matter iron through a model-based simultaneous analysis of magnetic susceptibility and R2* - A pilot study in patients with multiple sclerosis and normal controls. <i>NeuroImage</i> , 2019, 186, 308-320.	2.1	25
81	Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: A voxel-based morphometry study. <i>Pathophysiology</i> , 2011, 18, 53-60.	1.0	24
82	Influence of Personality on the Relationship Between Gray Matter Volume and Neuropsychiatric Symptoms in Multiple Sclerosis. <i>Psychosomatic Medicine</i> , 2013, 75, 253-261.	1.3	24
83	Gray matter SWI-filtered phase and atrophy are linked to disability in MS. <i>Frontiers in Bioscience - Elite</i> , 2013, E5, 525-532.	0.9	24
84	Longitudinal personality change associated with cognitive decline in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1909-1912.	1.4	24
85	Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS. <i>American Journal of Neuroradiology</i> , 2018, 39, 289-295.	1.2	24
86	Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 34, 103-111.	0.9	24
87	Monitoring of radiologic disease activity by serum neurofilaments in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	24
88	Improved assessment of multiple sclerosis lesion segmentation agreement via detection and outline error estimates. <i>BMC Medical Imaging</i> , 2012, 12, 17.	1.4	23
89	White matter tract network disruption explains reduced conscientiousness in multiple sclerosis. <i>Human Brain Mapping</i> , 2018, 39, 3682-3690.	1.9	23
90	Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1101-1111.	1.4	23

#	ARTICLE	IF	CITATIONS
91	Use of perfusion- and diffusion-weighted imaging in differential diagnosis of acute and chronic ischemic stroke and multiple sclerosis. <i>Neurological Research</i> , 2008, 30, 816-826.	0.6	22
92	Serum neurofilament light chain and optical coherence tomography measures in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	22
93	Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the Multi-Center SET study. <i>Journal of Neuroimmunology</i> , 2014, 273, 58-64.	1.1	21
94	Functional Connectivity and Structural Disruption in the Defaultâ€Mode Network Predicts Cognitive Rehabilitation Outcomes in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2020, 30, 523-530.	1.0	21
95	Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome. <i>Journal of the Neurological Sciences</i> , 2014, 338, 128-134.	0.3	20
96	A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Longâ€Term Comparative Study. <i>Journal of Neuroimaging</i> , 2017, 27, 620-629.	1.0	20
97	Neurocognition and Cerebral Lesion Burden in High-Risk Patients Before Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 384-392.	1.1	20
98	Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense â€black holesâ€: a post hoc magnetic resonance imaging analysis. <i>Journal of Neurology</i> , 2015, 262, 648-653.	1.8	19
99	Thalamic white matter in multiple sclerosis: A combined diffusionâ€tensor imaging and quantitative susceptibility mapping study. <i>Human Brain Mapping</i> , 2018, 39, 4007-4017.	1.9	19
100	Thalamic Nuclei Volumes and Their Relationships to Neuroperformance in Multiple Sclerosis: A Crossâ€Sectional Structural <sc>MRI</sc> Study. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 731-739.	1.9	19
101	A sensitive, noise-resistant method for identifying focal demyelination and remyelination in patients with multiple sclerosis via voxel-wise changes in magnetization transfer ratio. <i>Journal of the Neurological Sciences</i> , 2009, 282, 86-95.	0.3	18
102	Synergistic Effects of Reserve and Adaptive Personality in Multiple Sclerosis. <i>Journal of the International Neuropsychological Society</i> , 2016, 22, 920-927.	1.2	18
103	Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1077-1087.	1.4	18
104	Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both?. <i>Journal of Neurology</i> , 2021, 268, 2578-2588.	1.8	18
105	Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 344.	1.0	17
106	MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 821-834.	1.4	17
107	Staging and stratifying cognitive dysfunction in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 463-471.	1.4	17
108	Effect of Treatment with Interferon Beta-1a on Changes in Voxel-Wise Magnetization Transfer Ratio in Normal Appearing Brain Tissue and Lesions of Patients with Relapsingâ€Remitting Multiple Sclerosis: A 24-Week, Controlled Pilot Study. <i>PLoS ONE</i> , 2014, 9, e91098.	1.1	17

#	ARTICLE	IF	CITATIONS
109	Lower self-report fatigue in multiple sclerosis is associated with localized white matter tract disruption between amygdala, temporal pole, insula, and other connected structures. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 298-304.	0.9	16
110	Methods for the computation of templates from quantitative magnetic susceptibility maps (QSM): Toward improved atlas- and voxel-based analyses (VBA). <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 1474-1484.	1.9	15
111	A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS. <i>American Journal of Neuroradiology</i> , 2019, 40, 446-452.	1.2	15
112	Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	15
113	Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study. <i>Neurological Research</i> , 2012, 34, 761-769.	0.6	14
114	Tract-based spatial statistics analysis of diffusion-tensor imaging data in pediatric- and adult-onset multiple sclerosis. <i>Human Brain Mapping</i> , 2014, 35, 53-60.	1.9	14
115	An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice—The MS-MRIUS Study. <i>Journal of Neuroimaging</i> , 2017, 27, 339-347.	1.0	14
116	Atrophied brain lesion volume, a magnetic resonance imaging biomarker for monitoring neurodegenerative changes in multiple sclerosis. <i>Quantitative Imaging in Medicine and Surgery</i> , 2018, 8, 979-983.	1.1	14
117	Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 305-316.	0.6	14
118	Long-standing multiple sclerosis neurodegeneration: volumetric magnetic resonance imaging comparison to Parkinson's disease, mild cognitive impairment, Alzheimer's disease, and elderly healthy controls. <i>Neurobiology of Aging</i> , 2020, 90, 84-92.	1.5	14
119	Regional Specificity of Magnetization Transfer Imaging in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2008, 18, 130-136.	1.0	13
120	Application of hidden Markov random field approach for quantification of perfusion/diffusion mismatch in acute ischemic stroke. <i>Neurological Research</i> , 2008, 30, 827-834.	0.6	13
121	Immunologic and MRI markers of the therapeutic effect of IFN- β 1a in relapsing-remitting MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e176.	3.1	13
122	Effects of diet on brain iron levels among healthy individuals: an MRI pilot study. <i>Neurobiology of Aging</i> , 2015, 36, 1678-1685.	1.5	13
123	Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study. <i>American Journal of Neuroradiology</i> , 2018, 39, 1480-1486.	1.2	13
124	Late onset multiple sclerosis is associated with more severe ventricle expansion. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102588.	0.9	13
125	Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102653.	0.9	13
126	Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: Results of a 5-year follow-up study. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, S42-S48.	0.6	12

#	ARTICLE	IF	CITATIONS
127	Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. <i>BMC Neurology</i> , 2015, 15, 232.	0.8	12
128	Brain atrophy measurements should be used to guide therapy monitoring in MS – YES. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1522-1524.	1.4	12
129	Olfactory identification deficit predicts white matter tract impairment in Alzheimer's disease. <i>Psychiatry Research - Neuroimaging</i> , 2017, 266, 90-95.	0.9	12
130	Effect of teriflunomide on cortex-basal ganglia-thalamus (CxBGTh) circuit glutamatergic dysregulation in the Theiler's Murine Encephalomyelitis Virus mouse model of multiple sclerosis. <i>PLoS ONE</i> , 2017, 12, e0182729.	1.1	12
131	Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS. <i>Journal of Neuroimaging</i> , 2018, 28, 399-405.	1.0	12
132	Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 245-252.	1.4	12
133	Cortical and Deep Gray Matter Perfusion Associations With Physical and Cognitive Performance in Multiple Sclerosis Patients. <i>Frontiers in Neurology</i> , 2020, 11, 700.	1.1	12
134	Sex-specific Differences in Life Span Brain Volumes in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2020, 30, 342-350.	1.0	12
135	Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A case-control diffusion imaging study. <i>Pathophysiology</i> , 2011, 18, 61-68.	1.0	11
136	Regionally Distinct White Matter Lesions Do Not Contribute to Regional Gray Matter Atrophy in Patients with Multiple Sclerosis. , 2011, 21, 210-218.		11
137	MRI segmentation analysis in temporal lobe and idiopathic generalized epilepsy. <i>BMC Neurology</i> , 2014, 14, 131.	0.8	11
138	A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis. <i>Journal of Neurology</i> , 2020, 267, 802-811.	1.8	11
139	Conscientiousness and deterioration in employment status in multiple sclerosis over 3 years. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1125-1135.	1.4	11
140	MRI characteristics of familial and sporadic multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1145-1152.	1.4	10
141	Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders. <i>CNS Drugs</i> , 2019, 33, 1073-1086.	2.7	10
142	A preliminary investigation of cognitive intolerance and neuroimaging among adolescents returning to school after concussion. <i>Brain Injury</i> , 2020, 34, 820-829.	0.6	10
143	Diagnosis of depression in multiple sclerosis is predicted by frontal-parietal white matter tract disruption. <i>Journal of Neurology</i> , 2021, 268, 169-177.	1.8	10
144	DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2021, 30, 102652.	1.4	10

#	ARTICLE	IF	CITATIONS
145	Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study. <i>Multiple Sclerosis International</i> , 2013, 2013, 1-8.	0.4	9
146	Reserve-building activities in multiple sclerosis patients and healthy controls: a descriptive study. <i>BMC Neurology</i> , 2015, 15, 135.	0.8	9
147	Transcatheter aortic valve replacement: perioperative stroke and beyond. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 327-334.	1.4	9
148	Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2001-2013.	1.4	9
149	Functional network dynamics and decreased conscientiousness in multiple sclerosis. <i>Journal of Neurology</i> , 2022, 269, 2696-2706.	1.8	9
150	Effect of MRI coregistration on serial short-term brain volume changes in multiple sclerosis. <i>Neurological Research</i> , 2006, 28, 275-279.	0.6	8
151	Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis. <i>Neurological Research</i> , 2012, 34, 793-801.	0.6	8
152	Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2019, 29, 615-623.	1.0	8
153	Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1433-1436.	1.4	8
154	Detection of Monocyte/Macrophage and Microglia Activation in the TMEV Model of Chronic Demyelination Using USPIO-Enhanced Ultrahigh-Field Imaging. <i>Journal of Neuroimaging</i> , 2020, 30, 769-778.	1.0	8
155	Subcutaneous anti-CD20 antibody treatment delays gray matter atrophy in human myelin oligodendrocyte glycoprotein-induced EAE mice. <i>Experimental Neurology</i> , 2021, 335, 113488.	2.0	8
156	Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642097075.	1.5	7
157	Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy. <i>Fluids and Barriers of the CNS</i> , 2020, 17, 9.	2.4	7
158	The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2015, 25, 989-995.	1.0	6
159	Reserve-related activities and MRI metrics in multiple sclerosis patients and healthy controls: an observational study. <i>BMC Neurology</i> , 2016, 16, 108.	0.8	6
160	Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 65-73.	0.9	6
161	Interpretation of Brain Volume Increase in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2021, 31, 401-407.	1.0	6
162	Magnetization transfer imaging of acute black holes in patients on glatiramer acetate. <i>Frontiers in Bioscience - Elite</i> , 2012, E4, 1496.	0.9	5

#	ARTICLE	IF	CITATIONS
163	White Matter Hyperintensities on 1.5 and 3 Tesla Brain MRI in Healthy Individuals. <i>Journal of Biomedical Graphics and Computing</i> , 2013, 3, .	0.2	5
164	A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsingâ€“remitting multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2015, 8, 59-70.	1.5	5
165	High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117120.	0.3	5
166	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. <i>NeuroImage: Clinical</i> , 2021, 32, 102802.	1.4	5
167	Benchmarks of meaningful improvement on neurocognitive tests in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 487-491.	1.4	5
168	Improved operator agreement and efficiency using the minimum area contour change method for delineation of hyperintense multiple sclerosis lesions on FLAIR MRI. <i>BMC Medical Imaging</i> , 2013, 13, 29.	1.4	4
169	The Role of Highâ€“Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2018, 28, 328-337.	1.0	4
170	Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2020, 41, 1577-1583.	1.2	4
171	Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis. <i>Diagnostics</i> , 2020, 10, 685.	1.3	4
172	Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives. <i>Neurodegenerative Disease Management</i> , 2021, 11, 329-340.	1.2	4
173	Thalamic atrophy moderates associations among aerobic fitness, cognitive processing speed, and walking endurance in persons with multiple sclerosis. <i>Journal of Neurology</i> , 0, , .	1.8	4
174	Comment on “no evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset”. <i>Annals of Neurology</i> , 2011, 69, 1062-1063.	2.8	3
175	Impact of tissue atrophy on high-pass filtered MRI signal phase-based assessment in large-scale group-comparison studies: a simulation study. <i>Frontiers in Physics</i> , 2013, 1, .	1.0	3
176	No Regional Gray Matter Atrophy Differences between Pediatricâ€“and Adultâ€“Onset Relapsingâ€“Remitting Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2014, 24, 63-67.	1.0	3
177	Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsingâ€“remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly. <i>Journal of Neuroimmunology</i> , 2015, 281, 44-50.	1.1	3
178	Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes. <i>NeuroImage: Clinical</i> , 2021, 29, 102554.	1.4	3
179	Quantifying disease pathology and predicting disease progression in multiple sclerosis with only clinical routine T2-FLAIR MRI. <i>NeuroImage: Clinical</i> , 2021, 31, 102705.	1.4	3
180	Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 4796-4808.	1.8	3

#	ARTICLE	IF	CITATIONS
181	Diffusion tensor imaging reveals greater microstructure damage in lesional tissue that shrinks into cerebrospinal fluid in multiple sclerosis. <i>Journal of Neuroimaging</i> , 2021, 31, 995-1002.	1.0	3
182	Patient-Reported Outcome Severity and Emotional Salience Network Disruption in Multiple Sclerosis. <i>Brain Imaging and Behavior</i> , 2022, 16, 1252-1259.	1.1	3
183	Time course of lesion-induced atrophy in multiple sclerosis. <i>Journal of Neurology</i> , 2022, 269, 4478-4487.	1.8	3
184	Multisite MRI reproducibility of lateral ventricular volume using the NAIMS cooperative pilot dataset. <i>Journal of Neuroimaging</i> , 2022, 32, 910-919.	1.0	2
185	Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study. <i>International Journal of Molecular Sciences</i> , 2012, 13, 5659-5673.	1.8	1
186	Network Dynamics and Cognitive Impairment in Multiple Sclerosis: Functional MRI-based Decoupling of Complex Relationships. <i>Radiology</i> , 2019, 292, 458-459.	3.6	1
187	Measuring Aqueduct of Sylvius Cerebrospinal Fluid Flow in Multiple Sclerosis Using Different Software. <i>Diagnostics</i> , 2021, 11, 325.	1.3	1
188	MRI-based thalamic volumetry in multiple sclerosis using FSL-FIRST: Systematic assessment of common error modes. <i>Journal of Neuroimaging</i> , 2022, 32, 245-252.	1.0	1
189	Cerebral blood flow dependency on systemic arterial circulation in progressive multiple sclerosis. <i>European Radiology</i> , 2022, , 1.	2.3	1
190	Lower cerebral arterial blood flow is associated with greater serum neurofilament light chain levels in multiple sclerosis patients. <i>European Journal of Neurology</i> , 2022, , .	1.7	1
191	Title is missing!. <i>Journal of the Neurological Sciences</i> , 2005, 231, 103-104.	0.3	0
192	Reply. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1420.	1.1	0